头颈部鳞癌免疫检查点抑制剂治疗专家共识

近年来免疫检查点抑制剂（ICIs）在恶性肿瘤治疗中有着突破性进展，并迅速被批准作为多系统恶性肿瘤的一线治疗方案。在头颈部鳞癌中，帕博利珠单抗单药或联合化疗方案已被国内外指南推荐用于复发/转移头颈部鳞癌的一线治疗。虽然ICIs在头颈部鳞癌治疗中有里程碑的意义，但当前仍然存在诸多需要重视的问题，如ICIs疗效预测因子的选择，肿瘤病灶对ICIs治疗反应的评价，免疫超进展的应对以及免疫相关不良反应的处理等。因此，本共识基于当前临床已有的循证医学依据，结合临床上关注的热点问题进行深入探讨，整合头颈部肿瘤各专业领域专家的临床工作经验而形成相对规范统一的认识。

The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus

Immune checkpoint inhibitors (ICIs) present significant efficacy in the treatment of malignant tumors, and they have been approved as the first-line of treatment for various cancers. Pembrolizumab monotherapy or combined with chemotherapy has been recommended by domestic and foreign guidelines for the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma. Although ICIs represent a milestone in the treatment of head and neck squamous cell carcinoma, potential problems still need to be addressed, such as the selection of the efficacy predictors for ICIs, the evaluation of the tumor response to ICIs, and the treatment of immune hyperprogression and immune-related adverse events. Therefore, to form a relatively unified understanding of ICIs treatment for head and neck squamous cell carcinoma, we integrated the clinical experience of multi-disciplinary experts of head and neck cancers on the basis of current clinical hot issues and finally developed this consensus.